Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Sales and Divestitures (2024)

Insight Molecular Diagnostics (IMDX) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $17000.0 as the latest value for Q4 2024.

  • Quarterly Gains from Sales and Divestitures changed N/A to $17000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $17000.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $17000.0 for FY2024, N/A changed from the prior year.
  • Gains from Sales and Divestitures hit $17000.0 in Q4 2024 for Insight Molecular Diagnostics, up from $4000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $17000.0 in Q4 2024 to a low of $4000.0 in Q3 2024.